July 14, 2025
admin
Listing Review
The shares are listed at Rs. 250, marginal premium of 0.81% over the issue price.
Subscription Status
| Chemkart India IPO Subscription (Closed) | ||||
| QIB | NII x | RII x | Total x | Applications |
| 13.69 | 5.64 | 1.63 | 5.91 | 1975 |
| Subscription Review: Unimpressive subscription trend on the last day |
||||
What is the business of Chemkart India?
Chemkart India Limited: Powering Wellness with Precision Ingredients
Founded in 2015, Chemkart India Limited is a dynamic B2B distributor specializing in premium food and health ingredients. We connect global manufacturers with Indian businesses across diverse sectors—bridging continents, ensuring quality, and streamlining supply chains.
From sports nutrition to herbal extracts, we empower supplement manufacturers with a robust portfolio of scientifically supported, high-performance ingredients. Our mission is simple: to deliver variety, affordability, and quality with a focus on long-term customer partnerships.
End-to-End Capabilities
At our state-of-the-art 28,259 sq. ft. facility in Bhiwandi, Mumbai, we offer advanced grinding, blending, and packaging services in a hygienic, efficiency-driven environment. From precise labeling to secure sealing, we manage your ingredients with care and consistency.
Product Portfolio
- Amino Acids
Fundamental building blocks of proteins that drive biological processes and support metabolic health. - Health Supplements
Nutrient-rich blends infused with bioactive compounds to enhance overall wellbeing. - Herbal Extracts
Potent plant-based ingredients for therapeutic, functional, and natural health solutions. - Nucleotides
Bio-molecules essential for cellular health, gut integrity, and immune resilience. - Proteins
Core macronutrients vital for muscle development, immune support, and recovery. - Sports Nutrition
High-impact formulations designed to boost energy, endurance, and athletic performance. - Vitamins
Essential micronutrients that fuel physiological functions and safeguard wellness.
As of January 31, 2025, Chemkart India proudly employs 31 dedicated professionals who drive our mission forward—supporting innovation, compliance, and client success.
At Chemkart, we don’t just distribute ingredients—we deliver confidence, performance, and trust.
Chemkart India IPO Details
|
Sector: Food & Health supplement |
|
| IPO opens on | 7 July 2025 |
| IPO closes on | 9 July 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 32,29,900 Shares / Rs 80.10 Crore |
| * Fresh Issue | – |
| * Offer for Sale – | – Shares/ Rs.? Crore |
| Market Maker Portion | 1,66,200 Shares |
| Net offer to Public | 3063,700 Shares Rs.75.98 Crores |
| Face Value per share | Rs. 10 |
| Price Band | Rs. 236-248 |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | 600 Shares |
| Listing will at | BSE SME |
| Investor Category | Shares Offered | % | Rs. in Cr. |
| Market Maker | 166200 | ||
| QIB Shares | 1531850 | ||
| NII (HNI) | 459555 | 11.30 | |
| Retail | 1072295 | 26.59 | |
| Total | 3229900 | 100 | |
| Application | Lots | Shares | Amount, Rs. |
| Retail (Min) | 1 | 600 | 1,48,800 |
| Retail (Max) | 1 | 600 | 1,48,800 |
| HNI (Min) | 2 | 1200 | 2,97,600 |
Who are the Promoters of Chemkart India?
Mr. Ankit Shaileesh Mehta, Ms. Parul Shaileesh Mehta, and Mr. Shaileesh Vinodrai Mehta are the promoters of the company.
What are the Objects of Chemkart India IPO?
*Financing the capital expenditure towards setting up of the Manufacturing Facility through investment in the Wholly-Owned Subsidiary (WOS) Company, Easy Raw Materials Private Limited Rs. 36.22 Cr.
*Repayment/prepayment of all or certain of the borrowings availed of by the Company Rs. 20 Cr.
*General Corporate Purpose
Chemkart India IPO Timetable
Tentative timetable |
|
| IPO opens on | 7 July 2025 |
| IPO Closes on | 9 July 2025 |
| IPO Allotment on | 10 July 2025 |
| Refund Initiation | 11 July 2025 |
| Credit of Shares | 11 July 2025 |
| Listing on | 14 July 2025 |
| Registered Office of the Company Chemkart India Limited Office No. 403/404, 4th Floor, K.L. Accolade, 6th Road, TPS III, Santacruz (East), Mumbai – 400055 Mumbai, Maharashtra, 400055 |
| The Lead Manager of this IPO Smart Horizon Capital Advisor Pvt ltd |
|
Who is the Registrar to IPO? Bigshare Services Pvt ltd |
Chemkart India IPO GMP grey market premium, review, Subscription, allotment, listing estimate
Chemkart IndiaFinancials
| Period Ended | 30-Sep-24 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
| Assets | 85.48 | 53.51 | 37.48 | 24.54 |
| Revenue | 114.43 | 132.83 | 131.69 | 87.43 |
| Profit After Tax | 14.74 | 14.52 | 7.66 | 5.48 |
| Net Worth | 43.76 | 29.01 | 14.5 | 6.84 |
| Reserves and Surplus | 42.4 | 27.66 | 13.14 | 5.48 |
| Total Borrowing | 21.33 | 12.55 | 11.33 | 5.66 |
| Amount in Rs. Crore | ||||
Performance Indicators
| KPI | Values |
| ROE | 0.67% |
| ROCE | 0.51% |
| Debt/Equity | 0.43 |
| RoNW | 50.04% |
| EPS | |
| PE Ratio |
How Chemkart India IPO compares with the Peers?
There is no listed company having similar nature of the business
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Chemkart India IPO Review by Paresh Gordhandas, CA & Research Analyst.
Established in 2015, Chemkart India Limited has emerged as a dynamic B2B distributor, specializing in high-quality food and health ingredients. Acting as a vital link between global manufacturers and Indian businesses, Chemkart serves a wide range of sectors—ensuring consistent quality, efficient supply chains, and cross-border synergy.
The company offers a robust portfolio of scientifically backed ingredients, ranging from sports nutrition compounds to herbal extracts. It aims to empower supplement and health product manufacturers with a focus on innovation, affordability, and reliable sourcing. Built on long-term client relationships, Chemkart prioritizes trust, performance, and variety in every partnership.
On the financial front, the company has demonstrated strong growth in both revenue and profitability over the last three years. While its inventory and trade receivables are relatively high, they appear reasonable in proportion to the total revenue. Notably, the funds raised through the IPO are earmarked for investment in new plant and machinery. However, as this expansion is still in the early stages, it remains to be seen whether the returns from the new facility will be sufficient to justify the added capital burden.
-
Fundamental Perspective: So-So
-
Grey Market Sentiment: trades in the grey market for this IPO are not seen.
Quicklinks
